Savara Inc

The stock remains in a secular uptrend as 50- and 200-day SMAs slope higher, but short-term price is choppy between EMAs with neutral momentum. Medium-term bias is bullish on support near the 50-day SMA around $5.50–$5.60, yet entries should be deferred until a pullback into that area and confirmed acceptance off moving-average support rather than chasing the current consolidation near $5.75.

• ↑Phase 3 molgramostim data from IMPALA-2 suggests FDA approval
• ↑$10.94 target price implies ~97% upside potential
• ↓Negative earnings yield and weak profitability factors raise survival doubts